O

OmniAb Inc
NASDAQ:OABI

Watchlist Manager
OmniAb Inc
NASDAQ:OABI
Watchlist
Price: 1.84 USD -0.54% Market Closed
Market Cap: 264.9m USD

OmniAb Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

OmniAb Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
O
OmniAb Inc
NASDAQ:OABI
Net Income (Common)
-$62m
CAGR 3-Years
-32%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Net Income (Common)
$6.6B
CAGR 3-Years
-2%
CAGR 5-Years
6%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Net Income (Common)
$3.5B
CAGR 3-Years
-19%
CAGR 5-Years
0%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Net Income (Common)
$835.7m
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Net Income (Common)
$1.3B
CAGR 3-Years
1%
CAGR 5-Years
13%
CAGR 10-Years
13%
IQVIA Holdings Inc
NYSE:IQV
Net Income (Common)
$1.3B
CAGR 3-Years
3%
CAGR 5-Years
49%
CAGR 10-Years
13%
No Stocks Found

OmniAb Inc
Glance View

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.

OABI Intrinsic Value
1.65 USD
Overvaluation 10%
Intrinsic Value
Price
O

See Also

What is OmniAb Inc's Net Income (Common)?
Net Income (Common)
-62m USD

Based on the financial report for Dec 31, 2024, OmniAb Inc's Net Income (Common) amounts to -62m USD.

What is OmniAb Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-35%

Over the last year, the Net Income (Common) growth was -23%. The average annual Net Income (Common) growth rates for OmniAb Inc have been -32% over the past three years , -35% over the past five years .

Back to Top